![](https://img.etimg.com/thumb/msid-57202577,width-210,height-158,imgsize-341523,resizemode-75/.jpg)
Edited excerpts:
We believe that your Ahmedabad SEZ was also inspected in January last week. Can you confirm that for us, give us an indication of what happened there?
Yes the SEZ facility was also inspected in the last week of January and the inspection was smooth and only one of 483. This is a minor one which has already been addressed.
What is the status of your observation at the Ahmedabad SEZ and can you give us more details on that?
It was just simple process, change in SOP with respect to particular thing where the issuance authority to be changed which has been already done.
Sources indicate that the Baddi and Ankleshwar API will be inspected next, can you confirm that?
Our next facility which is going to be inspected is the Baddi facility.
When is that Baddi inspection happening?
It should be in next two weeks or so.
You have indicated that the Moraiya plant has got 483 no observations. Can we start expecting and anticipating new approvals from this plant?
Usually after the inspection is over, the report is submitted to the agency and the agency then study the report and finally releases the warning letter and then approval process starts. Our estimate is that it should take couple of months before we will start seeing product approval coming in.
Does this event also mean that the warning letter is lifted and you can get approvals immediately?
We had an inspection subsequent to the warning letter. The inspection was concluded without any observation and that's what we have informed the market. Based on that, we believe that now the warning letter will be lifted. However, there is a procedural aspect involved in lifting the warning letter and start giving approvals which may take couple of months as I mentioned.
Which are the major products that are filed in from this plant and since the start of the events with the US FDA? How many exactly have been transferred?
A very important part is that we have significant number of products which are pending approval from this plant including some key products like Lialda which will now be cleared for approval sooner. A significant part of our important products are from this facility.
The second point is that we have moved about 12 products out of this facility to our another facility. We have already got approval from a new facility and we have launched it. As far as the site transfer for pending approval product is concerned, we believe that though we have filled from other site, now we should be getting approval from Moraiya only.
Lialda, Prevacid and Toprol are filed from here, can they see a launch from here over the next six months?
I cannot give you a timeline. It depends upon when FDA approve but we believe that yes all of these important products would be launched in the financial year FY18.
Last time we believe that only the oral solid part was inspected and not the full plant. Was that the case now or was the entire facility inspected this time?
The entire facility was inspected.
Now you have 200 pending ANDA approvals, how many of these are filed from Moraya?
About 60 are from Moraya facility which are pending for approval and many of them we should see the approval coming in.
What has been the amount spent on the remediation of the Moraya plant till now?
I cannot give you a specific number but we invested over a period of last two years in terms of improving the overall automation in the plant and also doing significant work in the culture building for quality in the whole facility. I cannot give you the specific investment number but we have invested significantly to make the plant fully compliant and the result is that now that FDA was satisfied with our plant inspection.
In the conference call you said that the Cadila management expects at least 15-20 approvals every year ex Moraya, now how will this change post this clearance?
We should expect significant approval coming in, in FY18 we expect 40 plus approvals may be happening now.
Cadila has further gained market share in the Asacol HD to 60% what is the way ahead for this drug and would you have the option to launch your own version too?
I think Asacol, we have currently launched a generic, authorised generic and we currently intend to continue with authorised generic.
If you see the Q3 numbers, the EBITDA margin has fallen to a three-year low because of the high pricing pressure and the lack of new launches as well, do you think this clearance will now change this trend for you in the next quarter to come?
Definitely once we see the product approval happening, including some of the very important products, we will definitely see the margin improvement happening.
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2024 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2024 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price